MAP Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Still shy of its first birthday, MAP Pharmaceuticals Inc. has a lead product for pediatric asthma about to enter Phase II trials, a pulmonary delivery platform that has the potential to create highly-differentiated respiratory and systemic therapeutics, and $31.5 million in backing from committed, deep-pocketed investors.
You may also be interested in...
Drug Delivery's Product Risk and Reward
The great recognition of the drug delivery industry is that technologies don't sell--only drugs do. The result: drug delivery start-ups today must be drug companies, selling their best shot at using their technologies to create highly differentiated drug products. To do so, start-ups are pursuing two different visions. On the one hand are those who try to do as little as possible to the underlying molecule, thereby reducing risk and cost while relying on their system for product differentiation. On the other are those who believe that only important modifications to the molecule, or at least a deep understanding of the biology underlying a specific compound's therapeutic role, permit fundamental improvements in treatment.
In Vivo's Deals Of The Month, February 2018
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)
In Vivo's Deals Of The Month, January 2018
In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)